Cancer Type
Change My Cancer Selection

How Test Results Guide AML Treatment Choices

Save

How do doctors use AML test results to find the treatment approach that may work best for each patient? Dr. David Sallman explains how specific genetic mutations can guide personalized treatment decisions, including the use of targeted therapies and opportunities to participate in clinical trials.

Dr. David Sallman is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center where he specializes in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Learn more about Dr. Sallman.

Related Resources

Transcript

Katherine Banwell:

Dr. Sallman, how do test results help doctors determine which treatments may be most effective for an individual patient?

Dr. David Sallman:

Yeah, I mean, so really now, all of our treatment is based, so, for example, if you have a mutation of FLT3, I treat that one way. If you have a mutation of IDH1, IDH2, I treat that one way. NPM1, I treat that one way. KMT2A, I treat that one way. P53, and this is just the short list.

So, it really is everything. Now, I do think there are still some treatment approaches that really have kind of one approach for a younger, fit, and one approach for older, unfit. But there’s no question that outcomes can be significantly improved if the treatment is more personalized.

And that’s why, again, going to places that have – especially in the beginning, that’s the key – that have the sort of comprehensive and rapid workup, I think, is really key for most optimal care. Now, in the end, I work with many community oncologists, for example, throughout the Southeast U.S., and many of my patients may ultimately get a lot of their treatment done in the community. But that first – that very first – choice, that’s the critical one. And I think, actually, for AML care to get better and better, we actually have to further improve this sort of academic-community collaboration.

Katherine Banwell:

Can the presence of certain genetic changes indicate that targeted therapies may be the best option for a patient?

Dr. David Sallman:

Yeah, I mean, yeah. I mean, no question. Again, particularly for some of the ones that I already mentioned 3 – IDH, NPM1, KMT2A – I mean, this is already changing the standard of care now. As well as, again, is there a clinical trial that would give you access to maybe the most exciting agent? Many of the clinical trials enrolling are based on patients that have specific mutations.

Share On:

Facebook
Twitter
LinkedIn